呼吸器用生物製剤の世界市場レポート 2025年

呼吸器用生物製剤市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR16.7％で138億4,000万米ドルに成長します。予測期間中に予測される成長は、喘息やCOPDの有病率の上昇、生物学的療法の採用増加、研究開発への支出の増加、非侵襲的ドラッグデリバリー法に対する需要の高まり、償還政策の拡大などの要因によるものです。この期間の主な動向としては、呼吸器疾患に対するモノクローナル抗体の採用、生物学的製剤やドラッグデリバリー技術の進歩、規制当局の承認、大手企業間の戦略的提携や買収、創薬・開発における人工知能の統合などが挙げられます。

大気汚染レベルの高まりは、今後数年間の呼吸器用生物製剤市場の拡大を促進すると予想されます。大気汚染とは、大気中にガス、粒子状物質、生物学的分子などの有害物質が存在することを指し、人間の健康と環境の両方に悪影響を及ぼす可能性があります。大気汚染の増加は、工業化や都市化が進み、工場や自動車、建設活動からの排出量が増加したことが主な原因です。呼吸器用生物製剤は、空気中の汚染物質にさらされた人の炎症を抑え、肺の機能を高める標的療法を提供することで、大気汚染による健康への影響に対処する一助となります。例えば、2025年1月、米国環境保護庁（EPA）は、2023年に6,600万トン以上の汚染物質が大気中に放出されたと報告しました。さらに、2022年9月の国連環境計画によると、大気汚染は毎年700万人の早死をもたらし、世界人口の99％が汚染された空気を吸っています。その結果、大気汚染レベルの上昇が呼吸器用生物製剤市場の成長を促進しています。

呼吸器用生物製剤市場の主要企業は、慢性呼吸器疾患に対する標的免疫治療などの革新的な生物学的療法の開発に注力しており、炎症を抑え肺機能を高める精密な治療を提供しています。このような慢性呼吸器疾患の標的免疫療法は、身体の免疫系を管理して腫れを抑え、長期的な肺疾患における呼吸困難を緩和するように設計されています。例えば、フランスに本社を置く製薬会社サノフィS.A.は2024年9月、米国食品医薬品局（FDA）が好酸球表現型を有するコントロール不十分な慢性閉塞性肺疾患（COPD）の成人患者に対する追加維持療法としてデュピクセント（デュピルマブ）を承認したと発表しました。この承認は重要なマイルストーンであり、デュピクセントは米国で初めて、この特殊なCOPD患者群に対して承認された生物学的製剤となりました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界呼吸器用生物製剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の呼吸器用生物製剤市場：成長率分析
• 世界の呼吸器用生物製剤市場の実績：規模と成長, 2019-2024
• 世界の呼吸器用生物製剤市場の予測：規模と成長, 2024-2029, 2034F
• 世界呼吸器用生物製剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の呼吸器用生物製剤市場：疾患適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 喘息
• 慢性副鼻腔炎
• 好酸球増多症候群
• 世界の呼吸器用生物製剤市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈内
• 皮下
• 世界の呼吸器用生物製剤市場：販売チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• 小売薬局
• 通信販売薬局
• 世界の呼吸器用生物製剤市場喘息の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 重症好酸球性喘息
• アレルギー性喘息
• 非アレルギー性喘息
• 世界の呼吸器用生物製剤市場慢性副鼻腔炎の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 鼻ポリープを伴う慢性副鼻腔炎
• 鼻茸のない慢性副鼻腔炎
• 世界の呼吸器用生物製剤市場好酸球増多症候群（HES）のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 特発性HES
• リンパ球変異型HES
• 骨髄増殖性HES

第7章 地域別・国別分析

• 世界の呼吸器用生物製剤市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の呼吸器用生物製剤市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 呼吸器用生物製剤市場：競合情勢
• 呼吸器用生物製剤市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi S.A.
• AstraZeneca plc
• Novartis AG
• GlaxoSmithKline plc
• Amgen Inc.
• Viatris Inc.
• Regeneron Pharmaceuticals Inc.
• Boehringer Ingelheim International GmbH
• Biogen Inc.
• Vertex Pharmaceuticals Incorporated
• Swedish Orphan Biovitrum AB
• Glenmark Pharmaceuticals Ltd.
• Zymeworks Inc.
• Kiniksa Pharmaceuticals Ltd.
• Pieris Pharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 呼吸器用生物製剤市場2029：新たな機会を提供する国
• 呼吸器用生物製剤市場2029：新たな機会を提供するセグメント
• 呼吸器用生物製剤市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Respiratory biologics are a class of targeted therapies derived from living organisms, used to treat chronic respiratory conditions. These biologics typically focus on specific molecules in the immune system, such as interleukins (IL-4, IL-5, IL-13) or immunoglobulin E (IgE), to reduce inflammation and enhance breathing. They are primarily prescribed to patients with severe, uncontrolled respiratory diseases that do not respond adequately to standard treatments such as inhaled corticosteroids and bronchodilators.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary conditions treated with respiratory biologics include asthma, chronic rhinosinusitis, and hypereosinophilic syndrome. Asthma is a chronic inflammatory disorder of the airways that leads to breathing problems, wheezing, and coughing due to airway narrowing and heightened sensitivity. These biologics are available in various forms, such as intravenous and subcutaneous injections, and are distributed through different channels, including hospitals, specialty clinics, retail pharmacies, and mail-order pharmacies.

The respiratory biologics market research report is one of a series of new reports from The Business Research Company that provides respiratory biologics market statistics, including the respiratory biologics industry global market size, regional shares, competitors with the respiratory biologics market share, detailed respiratory biologics market segments, market trends, and opportunities, and any further data you may need to thrive in the respiratory biologics industry. These respiratory biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The respiratory biologics market size has grown rapidly in recent years. It will grow from $6.38 billion in 2024 to $7.47 billion in 2025 at a compound annual growth rate (CAGR) of 17.0%. The growth observed in the historical period can be attributed to several factors, including the rising prevalence of respiratory diseases, the growing adoption of personalized medicine, increased global healthcare spending, heightened awareness and diagnosis rates of respiratory conditions, and an expanding elderly population with respiratory disorders.

The respiratory biologics market size is expected to see rapid growth in the next few years. It will grow to $13.84 billion in 2029 at a compound annual growth rate (CAGR) of 16.7%. The growth projected for the forecast period can be attributed to factors such as the rising prevalence of asthma and COPD, increasing adoption of biologic therapies, higher spending on R&D, growing demand for non-invasive drug delivery methods, and the expansion of reimbursement policies. Key trends during this period include the adoption of monoclonal antibodies for respiratory diseases, advancements in biologic drug formulations and delivery techniques, regulatory approvals, strategic collaborations and acquisitions among major players, and the integration of artificial intelligence in drug discovery and development.

The growing levels of air pollution are expected to drive the expansion of the respiratory biologics market in the coming years. Air pollution refers to the presence of harmful substances, such as gases, particulate matter, and biological molecules, in the atmosphere, which can negatively impact both human health and the environment. The rise in air pollution is largely due to increased industrialization and urbanization, resulting in higher emissions from factories, vehicles, and construction activities. Respiratory biologics help address the health effects of air pollution by offering targeted therapies that reduce inflammation and enhance lung function in individuals exposed to airborne pollutants. For example, in January 2025, the United States Environmental Protection Agency (EPA) reported that over 66 million tons of pollutants were released into the atmosphere in 2023. Additionally, according to the United Nations Environment Programme in September 2022, air pollution causes 7 million premature deaths each year, and 99% of the global population breathes polluted air. Consequently, the rising levels of air pollution are driving the growth of the respiratory biologics market.

Leading companies in the respiratory biologics market are focusing on developing innovative biologic therapies, such as targeted immune treatments for chronic respiratory diseases, to provide precise treatments that reduce inflammation and enhance lung function. These targeted immune therapies for chronic respiratory diseases are designed to manage the body's immune system to reduce swelling and alleviate breathing difficulties in long-term lung conditions. For example, in September 2024, Sanofi S.A., a pharmaceutical company based in France, announced that the US Food and Drug Administration (FDA) had approved Dupixent (dupilumab) as an add-on maintenance therapy for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) who have an eosinophilic phenotype. This approval was a significant milestone, making Dupixent the first biologic medication authorized in the US for this particular group of COPD patients.

In February 2024, GlaxoSmithKline plc, a UK-based pharmaceutical company, acquired Aiolos Bio for an undisclosed amount. With this acquisition, GSK aims to enhance its respiratory and immunology portfolio by gaining access to Aiolos Bio's innovative treatments for inflammatory and immune-mediated diseases. Aiolos Bio is a US-based company focused on developing biological therapies for respiratory and inflammatory conditions.

Major players in the respiratory biologics market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Viatris Inc., Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Biogen Inc., Vertex Pharmaceuticals Incorporated, Swedish Orphan Biovitrum AB, Glenmark Pharmaceuticals Ltd., Zymeworks Inc., Kiniksa Pharmaceuticals Ltd., Pieris Pharmaceuticals Inc.

North America was the largest region in the respiratory biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in respiratory biologics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the respiratory biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The respiratory biologics market consists of sales of monoclonal antibodies (mAbs), interleukin inhibitors, and immunomodulators. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Respiratory Biologics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on respiratory biologics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for respiratory biologics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The respiratory biologics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Indication: Asthma; Chronic Rhinosinasitis; Hypereosinophilic Syndrome
• 2) By Route Of Administration: Intravenous; Subcuteneous
• 3) By Sales Channel: Hospitals; Specialty Clinics; Retail Pharmacies; Mail Order Pharmacies
• Subsegments::
• 1) By Asthma: Severe Eosinophilic Asthma; Allergic Asthma; Non-Allergic Asthma
• 2) By Type: Chronic Rhinosinusitis: Chronic Rhinosinusitis with Nasal Polyps; Chronic Rhinosinusitis without Nasal Polyps
• 3) By Hypereosinophilic Syndrome (HES): Idiopathic HES; Lymphocytic Variant HES; Myeloproliferative HES
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Respiratory Biologics Market Characteristics

3. Respiratory Biologics Market Trends And Strategies

4. Respiratory Biologics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Respiratory Biologics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Respiratory Biologics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Respiratory Biologics Market Growth Rate Analysis
• 5.4. Global Respiratory Biologics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Respiratory Biologics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Respiratory Biologics Total Addressable Market (TAM)

6. Respiratory Biologics Market Segmentation

• 6.1. Global Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Asthma
• Chronic Rhinosinasitis
• Hypereosinophilic Syndrome
• 6.2. Global Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous
• Subcuteneous
• 6.3. Global Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Retail Pharmacies
• Mail Order Pharmacies
• 6.4. Global Respiratory Biologics Market, Sub-Segmentation Of Asthma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Severe Eosinophilic Asthma
• Allergic Asthma
• Non-Allergic Asthma
• 6.5. Global Respiratory Biologics Market, Sub-Segmentation Of Chronic Rhinosinusitis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chronic Rhinosinusitis with Nasal Polyps
• Chronic Rhinosinusitis without Nasal Polyps
• 6.6. Global Respiratory Biologics Market, Sub-Segmentation Of Hypereosinophilic Syndrome (HES), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Idiopathic HES
• Lymphocytic Variant HES
• Myeloproliferative HES

7. Respiratory Biologics Market Regional And Country Analysis

• 7.1. Global Respiratory Biologics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Respiratory Biologics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Respiratory Biologics Market

• 8.1. Asia-Pacific Respiratory Biologics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Respiratory Biologics Market

• 9.1. China Respiratory Biologics Market Overview
• 9.2. China Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Respiratory Biologics Market

• 10.1. India Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Respiratory Biologics Market

• 11.1. Japan Respiratory Biologics Market Overview
• 11.2. Japan Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Respiratory Biologics Market

• 12.1. Australia Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Respiratory Biologics Market

• 13.1. Indonesia Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Respiratory Biologics Market

• 14.1. South Korea Respiratory Biologics Market Overview
• 14.2. South Korea Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Respiratory Biologics Market

• 15.1. Western Europe Respiratory Biologics Market Overview
• 15.2. Western Europe Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Respiratory Biologics Market

• 16.1. UK Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Respiratory Biologics Market

• 17.1. Germany Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Respiratory Biologics Market

• 18.1. France Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Respiratory Biologics Market

• 19.1. Italy Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Respiratory Biologics Market

• 20.1. Spain Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Respiratory Biologics Market

• 21.1. Eastern Europe Respiratory Biologics Market Overview
• 21.2. Eastern Europe Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Respiratory Biologics Market

• 22.1. Russia Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Respiratory Biologics Market

• 23.1. North America Respiratory Biologics Market Overview
• 23.2. North America Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Respiratory Biologics Market

• 24.1. USA Respiratory Biologics Market Overview
• 24.2. USA Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Respiratory Biologics Market

• 25.1. Canada Respiratory Biologics Market Overview
• 25.2. Canada Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Respiratory Biologics Market

• 26.1. South America Respiratory Biologics Market Overview
• 26.2. South America Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Respiratory Biologics Market

• 27.1. Brazil Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Respiratory Biologics Market

• 28.1. Middle East Respiratory Biologics Market Overview
• 28.2. Middle East Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Respiratory Biologics Market

• 29.1. Africa Respiratory Biologics Market Overview
• 29.2. Africa Respiratory Biologics Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Respiratory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Respiratory Biologics Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Respiratory Biologics Market Competitive Landscape And Company Profiles

• 30.1. Respiratory Biologics Market Competitive Landscape
• 30.2. Respiratory Biologics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Respiratory Biologics Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. AstraZeneca plc
• 31.3. Novartis AG
• 31.4. GlaxoSmithKline plc
• 31.5. Amgen Inc.
• 31.6. Viatris Inc.
• 31.7. Regeneron Pharmaceuticals Inc.
• 31.8. Boehringer Ingelheim International GmbH
• 31.9. Biogen Inc.
• 31.10. Vertex Pharmaceuticals Incorporated
• 31.11. Swedish Orphan Biovitrum AB
• 31.12. Glenmark Pharmaceuticals Ltd.
• 31.13. Zymeworks Inc.
• 31.14. Kiniksa Pharmaceuticals Ltd.
• 31.15. Pieris Pharmaceuticals Inc.

32. Global Respiratory Biologics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Respiratory Biologics Market

34. Recent Developments In The Respiratory Biologics Market

35. Respiratory Biologics Market High Potential Countries, Segments and Strategies

• 35.1 Respiratory Biologics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Respiratory Biologics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Respiratory Biologics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34949_Respiratory_Biologics_GMR_2025